D. Singh, G. Criner, M. Dransfield, D. Halpin, M. Han, C. E. Jones, S. Kilbride, P. Lange, D. Lomas, F. Martinez, S. Pascoe, R. Wise, David A. Lipson
{"title":"告知COPD治疗途径(IMPACT研究):COPD患者单吸入器三联治疗(糠酸氟替卡松/维兰特罗/乌莫利维尼/维兰特罗)与糠酸氟替卡松/维兰特罗和乌莫利维尼/维兰特罗:基于基线COPD药物使用的分析","authors":"D. Singh, G. Criner, M. Dransfield, D. Halpin, M. Han, C. E. Jones, S. Kilbride, P. Lange, D. Lomas, F. Martinez, S. Pascoe, R. Wise, David A. Lipson","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1116","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":131398,"journal":{"name":"A24. COPD: THERAPY, IMAGING, AND MOLECULAR MARKERS","volume":"227 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use\",\"authors\":\"D. Singh, G. Criner, M. Dransfield, D. Halpin, M. Han, C. E. Jones, S. Kilbride, P. Lange, D. Lomas, F. Martinez, S. Pascoe, R. Wise, David A. Lipson\",\"doi\":\"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":131398,\"journal\":{\"name\":\"A24. COPD: THERAPY, IMAGING, AND MOLECULAR MARKERS\",\"volume\":\"227 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"A24. COPD: THERAPY, IMAGING, AND MOLECULAR MARKERS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1116\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"A24. COPD: THERAPY, IMAGING, AND MOLECULAR MARKERS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use